Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data | Zendy

George G. Zhanel | Zendy; K. Wolter | Zendy; Cristina Calciu | Zendy; Patricia A. Hogan | Zendy; Donald E. Low | Zendy; Karl Heinz Weiss | Zendy; James A. Karlowsky | Zendy

Open Access

Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data

Author(s) -

George G. Zhanel,

K. Wolter,

Cristina Calciu,

Patricia A. Hogan,

Donald E. Low,

Karl Heinz Weiss,

James A. Karlowsky

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku207

Subject(s) - azithromycin , medicine , streptococcus pneumoniae , pneumonia , bronchitis , otitis , respiratory tract infections , gastroenterology , community acquired pneumonia , chronic bronchitis , antibacterial agent , surgery , respiratory system , antibiotics , microbiology and biotechnology , biology

Community-acquired respiratory tract infections (CARTI) are commonly caused by Streptococcus pneumoniae (SPN) and empirically treated with azithromycin. This study assessed clinical cure rates in azithromycin-treated subjects with CARTI caused by azithromycin-susceptible (Azi-S) or azithromycin-resistant (Azi-R) SPN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research